UY31017A1 - Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. - Google Patents
Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica.Info
- Publication number
- UY31017A1 UY31017A1 UY31017A UY31017A UY31017A1 UY 31017 A1 UY31017 A1 UY 31017A1 UY 31017 A UY31017 A UY 31017A UY 31017 A UY31017 A UY 31017A UY 31017 A1 UY31017 A1 UY 31017A1
- Authority
- UY
- Uruguay
- Prior art keywords
- alpha
- treatment
- allergic
- antihistaminic
- tumor necrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
Se describen métodos para el tratamiento de pacientes con conjuntivitis alérgica y rinitis alérgica que incluyen la administracion topica de una composicion que comprende una cantidad eficaz farnacéuticamente de un antagonista de H1 y un compuesto bloqueador del TNFa(alfa).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91117607P | 2007-04-11 | 2007-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31017A1 true UY31017A1 (es) | 2008-07-03 |
Family
ID=39523827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31017A UY31017A1 (es) | 2007-04-11 | 2008-04-10 | Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20080254029A1 (es) |
EP (1) | EP2131834A2 (es) |
JP (1) | JP2010523695A (es) |
KR (1) | KR20100014565A (es) |
CN (1) | CN101641094A (es) |
AR (1) | AR066016A1 (es) |
AU (1) | AU2008240279A1 (es) |
BR (1) | BRPI0810893A2 (es) |
CA (1) | CA2682730A1 (es) |
CL (1) | CL2008001038A1 (es) |
MX (1) | MX2009010946A (es) |
RU (1) | RU2009141592A (es) |
TW (1) | TW200902025A (es) |
UY (1) | UY31017A1 (es) |
WO (1) | WO2008127975A2 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
WO2007035873A1 (en) * | 2005-09-21 | 2007-03-29 | Pharmacopeia, Inc. | Purinone derivatives for treating neurodegenerative diseases |
US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
US7915268B2 (en) * | 2006-10-04 | 2011-03-29 | Wyeth Llc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
CL2007002866A1 (es) * | 2006-10-04 | 2008-07-04 | Pharmacopeia Inc | Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m |
US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
US20090182035A1 (en) * | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
CA2691914C (en) * | 2007-07-11 | 2012-06-26 | Pfizer Inc. | Pharmaceutical compositions and methods of treating dry eye disorders |
EP2408453B1 (en) | 2009-03-17 | 2022-01-05 | Nicox Ophthalmics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
US8569273B2 (en) | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
EP2421867B1 (en) | 2009-04-20 | 2015-09-02 | Auspex Pharmaceuticals, Llc | Piperidine inhibitors of janus kinase 3 |
GB0921803D0 (en) * | 2009-12-14 | 2010-01-27 | Biocopea Ltd | Drug composition and its use in therapy |
EP2295535A1 (en) * | 2009-09-11 | 2011-03-16 | Mead Johnson Nutrition Company | Probiotic material |
MX2012003693A (es) * | 2009-10-01 | 2012-04-19 | Alcon Res Ltd | Composiciones de olopatadine y usos de las mismas. |
HUE026106T2 (en) * | 2010-10-06 | 2016-05-30 | Bausch & Lomb | Bepotastine preparations |
BR112013017183A2 (pt) | 2011-01-04 | 2017-07-25 | Bausch & Lomb | composições de bepostatina |
MX2013009972A (es) * | 2011-04-08 | 2013-09-26 | Pfizer | Formas cristalinas y no cristalinas de tofacitinib y composicion farmaceutica que comprende tofacitinib y un potenciador de penetracion. |
JP6463968B2 (ja) * | 2011-07-01 | 2019-02-06 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | アルギニンを含まない腫瘍壊死因子受容体:fc融合ポリペプチド組成物およびその使用方法 |
US10493151B2 (en) * | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
SG11201405475UA (en) * | 2012-03-07 | 2014-10-30 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha antibodies |
US20150307619A1 (en) * | 2012-12-13 | 2015-10-29 | The Schepens Eye Research Institute, Inc. | Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors |
CN103202833A (zh) * | 2012-12-25 | 2013-07-17 | 常州市亚邦医药研究所有限公司 | 一种奥洛他定或其盐的药用组合物及其制备方法 |
GB201509893D0 (en) * | 2015-06-08 | 2015-07-22 | Ucb Biopharma Sprl | Therapeutic agents |
MX2021001186A (es) | 2015-11-20 | 2022-10-11 | Forma Therapeutics Inc | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. |
WO2019245015A1 (ja) * | 2018-06-22 | 2019-12-26 | 参天製薬株式会社 | デスロラタジン又はその塩を含有する医薬組成物 |
JP2020090448A (ja) * | 2018-12-04 | 2020-06-11 | 学校法人順天堂 | アレルギー性結膜炎予防又は治療剤 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4501729A (en) * | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
US4699880A (en) * | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
GB8520662D0 (en) * | 1985-08-17 | 1985-09-25 | Wellcome Found | Tricyclic aromatic compounds |
US4923892A (en) * | 1985-08-17 | 1990-05-08 | Burroughs Wellcome Co. | Tricyclic aromatic compounds |
JPS6310784A (ja) * | 1986-03-03 | 1988-01-18 | Kyowa Hakko Kogyo Co Ltd | 抗アレルギー剤 |
IL83878A (en) * | 1987-09-13 | 1995-07-31 | Yeda Res & Dev | Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it |
US5336603A (en) * | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
US5935978A (en) * | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
US6284471B1 (en) * | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
IL101850A (en) * | 1991-06-13 | 1996-01-31 | Janssen Pharmaceutica Nv | History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them |
JP3251587B2 (ja) * | 1992-04-02 | 2002-01-28 | スミスクライン・ビーチャム・コーポレイション | 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物 |
DE69328778T2 (de) * | 1992-04-02 | 2000-11-23 | Smithkline Beecham Corp | Verbindungen für die behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor |
US5552438A (en) * | 1992-04-02 | 1996-09-03 | Smithkline Beecham Corporation | Compounds useful for treating allergic and inflammatory diseases |
US5891904A (en) * | 1992-09-14 | 1999-04-06 | Wolf-Georg Forssmann | Use of inhibitors of phosphodiesterase IV |
US6270766B1 (en) * | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
GB9312853D0 (en) * | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
US5594106A (en) * | 1993-08-23 | 1997-01-14 | Immunex Corporation | Inhibitors of TNF-α secretion |
US5858981A (en) * | 1993-09-30 | 1999-01-12 | University Of Pennsylvania | Method of inhibiting phagocytosis |
US5708142A (en) * | 1994-05-27 | 1998-01-13 | Genentech, Inc. | Tumor necrosis factor receptor-associated factors |
US5922751A (en) * | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
US5712381A (en) * | 1994-10-19 | 1998-01-27 | Genetics Institute, Inc. | MADD, a TNF receptor death domain ligand protein |
US5852173A (en) * | 1994-10-19 | 1998-12-22 | Genetics Institute, Inc. | TNF receptor death ligand proteins and inhibitors of ligand binding |
JPH10511391A (ja) * | 1994-12-23 | 1998-11-04 | スミスクライン・ビーチャム・コーポレイション | 3,3−(二置換)シクロヘキサン−1−オール二量体および関連化合物 |
US5563039A (en) * | 1995-03-31 | 1996-10-08 | Tularik, Inc. | TNF receptor-associated intracellular signaling proteins and methods of use |
US5658877A (en) * | 1995-05-18 | 1997-08-19 | Wisconsin Alumni Research Foundation | Method to treat endotoxin effects by administration of 33 kilodalton phospholipid binding protein |
US5641805A (en) * | 1995-06-06 | 1997-06-24 | Alcon Laboratories, Inc. | Topical ophthalmic formulations for treating allergic eye diseases |
ZA966663B (en) * | 1995-08-17 | 1998-02-06 | Genentech Inc | Traf Inhibitors. |
US5935966A (en) * | 1995-09-01 | 1999-08-10 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions |
US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
NZ327044A (en) * | 1996-01-11 | 2000-01-28 | Smithkline Beecham Corp | Substituted imidazole compounds |
FR2746800B1 (fr) * | 1996-03-29 | 1998-06-05 | Jouveinal Inst Rech | Diazepino-indoles inhibiteurs de phosphodiesterases 4 |
GB9607120D0 (en) * | 1996-04-04 | 1996-06-12 | Chiroscience Ltd | Compounds |
US5948786A (en) * | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
US5891924A (en) * | 1996-09-26 | 1999-04-06 | Research Development Foundation | Curcumin (diferuloylmethane) inhibition of NFκB activation |
US5994620A (en) * | 1996-12-10 | 1999-11-30 | The Jackson Laboratory | Induced chromosomal deletion |
US5932425A (en) * | 1997-02-18 | 1999-08-03 | Signal Pharmaceuticals, Inc. | Compositions and methods for modulating cellular NF-κB activation |
US5905089A (en) * | 1997-04-14 | 1999-05-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Use of sesquiterpene lactones for treatment of severe inflammatory disorders |
FR2762841B1 (fr) * | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
WO1998052937A2 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
US5939421A (en) * | 1997-07-01 | 1999-08-17 | Signal Pharmaceuticals, Inc. | Quinazoline analogs and related compounds and methods for treating inflammatory conditions |
KR20000068711A (ko) * | 1997-08-06 | 2000-11-25 | 도리이 신이치로 | Ⅳ형 포스포디에스테라제 억제제로서의 1-아릴-1,8-나프틸리딘-4-온 유도체 |
IT1296984B1 (it) * | 1997-12-19 | 1999-08-03 | Zambon Spa | Derivati ftalazinici inibitori della fosfodiesterasi 4 |
UA59443C2 (uk) * | 1998-04-28 | 2003-09-15 | Арцнайміттельверк Дрезден Гмбх | Гідроксііндол, спосіб його одержання, лікарська форма на його основі та спосіб її одержання |
PT1086096E (pt) * | 1998-06-10 | 2003-12-31 | Altana Pharma Ag | Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4 |
AU754379B2 (en) * | 1998-08-26 | 2002-11-14 | Smithkline Beecham Corporation | Therapies for treating pulmonary diseases |
IT1302677B1 (it) * | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
IT1303272B1 (it) * | 1998-10-29 | 2000-11-06 | Zambon Spa | Derivati triciclici inibitori della fosfodiesterasi 4 |
BR9804993A (pt) * | 1998-11-10 | 2000-06-06 | Panacea Biotec Ltd | Composição antialérgica e antiinflamatória |
US6225317B1 (en) * | 1998-11-19 | 2001-05-01 | Dupont Pharmaceuticals Company | Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone |
BR0107964A (pt) * | 2000-01-31 | 2002-10-29 | Pfizer Prod Inc | Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4 |
DE60103976T2 (de) * | 2000-01-31 | 2005-07-21 | Pfizer Products Inc., Groton | Pyrimidinylcarboxamiden als inhibitoren der pde4 isoenzyme |
US20060018907A1 (en) * | 2000-08-07 | 2006-01-26 | Centocor, Inc. | Anti-TNF antibodies and peptides of human tumor necrosis factor |
UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
EP2298789B1 (en) * | 2000-09-08 | 2012-03-14 | Schering Corporation | Mammalian genes; related reagents and methods |
US6740666B2 (en) * | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
AU2002257459B2 (en) * | 2001-05-24 | 2006-12-14 | Merck Frosst Canada Ltd | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
GB0115181D0 (en) * | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Novel use |
TWI231759B (en) * | 2001-06-27 | 2005-05-01 | Alcon Inc | Olopatadine formulations for topical administration |
GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
US20030113828A1 (en) * | 2001-11-09 | 2003-06-19 | Ginsberg Mark H. | Compositions and methods for modulating Syk function |
US20030158195A1 (en) * | 2001-12-21 | 2003-08-21 | Cywin Charles L. | 1,6 naphthyridines useful as inhibitors of SYK kinase |
TWI347845B (en) * | 2002-03-06 | 2011-09-01 | Nycomed Gmbh | Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same |
US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
NZ540138A (en) * | 2002-11-19 | 2008-07-31 | Memory Pharm Corp | Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
AR042194A1 (es) * | 2002-11-22 | 2005-06-15 | Merck & Co Inc | Metodo para preparar inhibidores de fosfodiesterasa - 4 |
IS7839A (is) * | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
US6909002B2 (en) * | 2002-11-22 | 2005-06-21 | Merck & Co., Inc. | Method of preparing inhibitors of phosphodiesterase-4 |
US20040105856A1 (en) * | 2002-12-02 | 2004-06-03 | Robin Thurmond | Use of histamine H4 receptor antagonist for the treatment of inflammatory responses |
US20060177430A1 (en) * | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
EP2371835A1 (en) * | 2003-07-03 | 2011-10-05 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
US20050192261A1 (en) * | 2003-09-15 | 2005-09-01 | Jost-Price Edward R. | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2005049838A2 (en) * | 2003-11-14 | 2005-06-02 | Yale University | Syk-targeted nucleic acid interference |
MY141255A (en) * | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
US20050254212A1 (en) * | 2004-05-17 | 2005-11-17 | Eins Oe-Tech Co., Ltd. | Heat dissipation module for electronic device |
CA2573259A1 (en) * | 2004-07-06 | 2006-02-09 | Bioren Inc. | High affinity anti-tnf-alpha antibodies and method |
-
2008
- 2008-04-10 TW TW097112986A patent/TW200902025A/zh unknown
- 2008-04-10 RU RU2009141592/15A patent/RU2009141592A/ru not_active Application Discontinuation
- 2008-04-10 KR KR1020097019961A patent/KR20100014565A/ko not_active Application Discontinuation
- 2008-04-10 CA CA002682730A patent/CA2682730A1/en not_active Abandoned
- 2008-04-10 BR BRPI0810893-5A2A patent/BRPI0810893A2/pt not_active Application Discontinuation
- 2008-04-10 AR ARP080101489A patent/AR066016A1/es unknown
- 2008-04-10 MX MX2009010946A patent/MX2009010946A/es unknown
- 2008-04-10 EP EP08745485A patent/EP2131834A2/en not_active Withdrawn
- 2008-04-10 UY UY31017A patent/UY31017A1/es not_active Application Discontinuation
- 2008-04-10 AU AU2008240279A patent/AU2008240279A1/en not_active Abandoned
- 2008-04-10 JP JP2010503203A patent/JP2010523695A/ja active Pending
- 2008-04-10 US US12/100,715 patent/US20080254029A1/en not_active Abandoned
- 2008-04-10 CN CN200880009226A patent/CN101641094A/zh active Pending
- 2008-04-10 WO PCT/US2008/059885 patent/WO2008127975A2/en active Application Filing
- 2008-04-11 CL CL2008001038A patent/CL2008001038A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2008127975A2 (en) | 2008-10-23 |
JP2010523695A (ja) | 2010-07-15 |
AU2008240279A1 (en) | 2008-10-23 |
US20080254029A1 (en) | 2008-10-16 |
CL2008001038A1 (es) | 2009-01-16 |
RU2009141592A (ru) | 2011-05-20 |
TW200902025A (en) | 2009-01-16 |
CN101641094A (zh) | 2010-02-03 |
WO2008127975A3 (en) | 2009-07-30 |
MX2009010946A (es) | 2009-10-29 |
EP2131834A2 (en) | 2009-12-16 |
CA2682730A1 (en) | 2008-10-23 |
BRPI0810893A2 (pt) | 2014-10-29 |
KR20100014565A (ko) | 2010-02-10 |
AR066016A1 (es) | 2009-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31017A1 (es) | Uso de un inhibidor del factor &(alfa) de necrosis tumoral mas un antihistaminico para el tratamiento de la rinitis alérgica y la conjuntivitis alérgica. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
CL2007003523A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer | |
CL2007003520A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer. | |
CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
CL2008002369A1 (es) | Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer. | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CL2007001870A1 (es) | Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d | |
NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
CL2008002521A1 (es) | Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer. | |
CL2012000772A1 (es) | Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata. | |
CL2007002166A1 (es) | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. | |
ECSP099724A (es) | Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
CL2011002787A1 (es) | Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica. | |
CL2008002049A1 (es) | Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c. | |
CL2015002534A1 (es) | Formulaciones combinadas de neosaxitoxina para una anestesia local prolongada | |
AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20200115 |